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Around 44 million people in the world are suffering from demen-
tia including Alzheimer’s disease (AD). It is considered as one of
the biggest global public health challenges our generation cope
with. At the dawn of 2015, AD medical care remains unsuccess-
ful despite the identification of its neuropathological hallmarks
one century ago. Being attentive to emerging prospects is essen-
tial because the current advances lead to substantive improvement
of the medical care. We are pleased to present an issue specifically
devoted to AD and to the related therapeutic strategies. The Topic
Research in this issue is based on a series of original papers and
reviews. The latters focus on the advances in basic and clinical
research trends in AD, they provide an up-to-date information
and future perspectives on this hot topic as well.
AD is a progressive disease, it occurs over a long period before
the onset of symptoms which are impaired memory, apathy, and
depression. The characteristics of AD consist in neurofibrillary
tangles (intraneuronal aggregates of hyperphosphorylated tau
proteins) and senile plaques [dense extraneuronal deposits com-
posed of amyloid β (Aβ)]. The other features linked to these two
core pathological hallmarks of AD are inflammation, oxidative
stress, progressive synaptic, and neuronal loss. Nowadays, many
AD molecular patterns have been screened to identify a poten-
tial therapeutic strategy. Although a myriad of evidence shows
that the hippocampal volume decrease belongs to the AD earli-
est signs, as it is pointed out by the authors of the review paper
presented in this issue, this element clearly could not be used as a
diagnostic criterion (Maruszak and Thuret, 2014).
With the flood of evidence for tau pathology as key event of
the disease development, the understanding of diverse tau func-
tions and its molecular behavior is one of the major steps in
the progression of our knowledge about the neurodegenerescence
detected in AD. The precision of tau role in DNA protection
and RNA integrity under physiological conditions or under ROS-
producing stress (Violet et al., 2014) provides clarification for a
mechanistic model in which tau disturbance initiates an expla-
nation for DNA damages observed in AD. Principally, tau is a
phosphoprotein. So, a complex equilibrium between tau kinases
and phosphatases activities is one of the main potential thera-
peutic runways. Abnormal or excessive tau phosphorylation by
either kinases such as GSK3β, CDK5, DYRK1A for example or
other known and unknown kinases are related to AD patho-
genesis. However, the identity and the strict number of tau
kinases involved in AD process remain uncertain. In this way,
focus at specific tau phosphorylation site(s) by a kinase mul-
titargeting approach as potential AD therapeutic strategy has
been proposed to effectively hamper the multifactorial disease
progression (Hilgeroth and Tell, 2013). Since diabetes, linked
itself to dysregulation of GSK3β activity, is associated in late-
life with an increased risk of dementia, epidemiological and
experimental studies are summarized in this issue in order to
understand the effects of diabetes mellitus on tau pathogenesis.
In fact, the authors discuss herein a link between tau, dia-
betes mellitus and the cognitive impairment (El Khoury et al.,
2014). On the other hand, Peptidyl-prolyl cis-trans Isomerase
NIMA-interacting 1 (Pin1), which plays a role in the balance of
phosphorylation/dephosphorylation of tau, has been suspected of
participating in a common mechanism between AD and hypoxia.
The pathophysiological relevance of Hypoxia-inducible factor 1α
(HIF-1α) pathway regulation in APP amyloidogenic metabolism
has been explored in order to clarify the relationship between
AD and hypoxia (Lonati et al., 2014). Among tau-based ther-
apeutic strategies, the one which limits the spreading of tau
pathology without affecting tau intracellular functions is espe-
cially attractive (Medina and Avila, 2014). Strong support for
this idea comes from the importance of tau for Aβ-induced
synaptotoxicity. In addition to this, high concentration of Aβ
inhibits synaptic activity and in turn, it involves toxicity for the
targeted synapses (Wang et al., 2013). According to this strat-
egy, synaptic inhibitory systems could help to compensate neu-
rotransmission imbalance (Nava-Mesa et al., 2014). Moreover,
natural anti-inflammatory components, as Andrean Compound,
has been studied as a preventive or adjuvant agent in AD
(Maccioni et al., 2014).
Accumulation of Aβ is induced when the equilibrium between
its production and clearance is disrupted. Thus, amyloid-based
therapeutic strategies target this balance but numerous trials
were unsuccessful for reasons of specificity or biodisponibility.
However, the restoration of the microglial homeostasy and the
targeting of Triggering Receptor Expressed on Myeloid cells 2
(TREM2) pathway can constitute an elegant therapeutic strat-
egy (Zhao and Lukiw, 2013). Compounds are yet available to
improve the microglia-dependent clearance of Aβ, and this strat-
egy would benefit from in vivo experiments (Jones et al., 2014).
Furthermore, diversity of gut microbiota changes through life
stages and alterations of this ecosystem have been associated
with diverse diseases. Therapeutic modulation of gut microbiota
could constitute a promising adjuvant therapy in central neu-
rodegenerative disorders. An opinion article proposes probiotics
as a prophylactic treatment to prevent AD in its early stages
(Bhattacharjee and Lukiw, 2013).
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Several recent key advances in the field of AD understanding
and treatment are presented in this thematic issue. Ultimately, we
hope that you will enjoy as us to read these papers and reviews
presented in this special issue. The coming years certainly promise
a time for completion of a new era in the history of the AD under-
standing and emerging therapies. AD understanding is within
reach. Stay tuned.
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